Our mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.
Prolacta Bioscience is a privately held, life sciences company dedicated to improving the quality of life in the most fragile infants through the harmony of nature and science. We create specialty formulations made from human milk for the nutritional needs of premature infants in neonatal intensive care units (NICU). These formulations are sold to NICUs around the country.
Prolacta developed the first large scale human milk processing facility in the world. Using state-of-the-art formulation, pasteurization and filling processes, we formulate human milk to an exact standard to meet the needs of very low birth weight babies during the first 30 days of life.
Prolacta is committed to supporting research in the study of human milk and premature infant nutrition in order to make a difference in the lives of the most fragile premature babies.
Sobi is dedicated to developing and delivering innovative therapies to improve the lives of rare disease patients.
Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
- Key areas of focus are inflammation and genetic diseases.
- We have world-class capabilities in protein biochemistry and biologics manufacturing development – validated by leading industry partners.
We are an organization covering over 20 countries in Europe as well as the U.S. and Canada.
Improving the lives of people with acute, rare and chronic disorders.
Chiesi USA is the U.S. affiliate of Chiesi Farmaceutici, S.p.A, a global R&D-focused pharmaceutical company located in Parma, Italy. We are a specialty pharmaceutical company committed to the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings.
As an organization, we have a strong track record of performance. This has allowed the company to grow quickly in terms of sales, people and product portfolio. With revenues exceeding $275 million in 2018, Chiesi USA has quickly established itself as a top producing affiliate in the Chiesi worldwide group.
Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.